ArriVent BioPharma (AVBP) vs Monte Rosa Therapeutics (GLUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monte Rosa Therapeutics (GLUE) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 33.9% versus a loss of 12.5%. Monte Rosa Therapeutics is the larger company by market cap ($880.4 million vs $823.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | GLUE |
|---|---|---|
| Share price | $16.71 | $10.32 |
| Market cap | $823.93M | $880.43M |
| 1-day change | -1.07% | +1.47% |
| YTD return | -16.05% | -34.18% |
| 1-year return | -12.53% | +33.85% |
| 5-year return | — | -51.32% |
| EPS (TTM) | $-3.62 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $25.77 |
| 52-week low | $11.36 | $7.65 |
| Distance from 52-week high | -53.36% | -59.95% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +82.53% | +171.32% |
| Average volume | 881.59K | 1.31M |
| Shares outstanding | 49.31M | 85.31M |
| Employees | 77 | 173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLUE has outperformed AVBP by 46.4 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
AVBP vs GLUE FAQ
Which is bigger, ArriVent BioPharma or Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $880.43M compared with $823.93M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, AVBP or GLUE?
GLUE returned +33.85% over the past 12 months, compared with -12.53% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Monte Rosa Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ArriVent BioPharma and Biotechnology: Biological Products (No Diagnostic Substances) for Monte Rosa Therapeutics.